Patents by Inventor Ken Liljegren
Ken Liljegren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110046218Abstract: The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100° C., as well as a method for making such an orodispersible tablet.Type: ApplicationFiled: November 1, 2010Publication date: February 24, 2011Applicant: H. LUNDBECK A/SInventors: Robert Dancer, Hans Petersen, Ole Nielsen, Michael Harold Rock, Helle Eliasen, Ken Liljegren
-
Patent number: 7834201Abstract: The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100° C., as well as a method for making such an orodispersible tablet.Type: GrantFiled: June 21, 2006Date of Patent: November 16, 2010Assignee: H. Lundbeck A/SInventors: Robert Dancer, Hans Petersen, Ole Nielsen, Michael Harold Rock, Helle Eliasen, Ken Liljegren
-
Patent number: 7723533Abstract: The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzo-furancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100° C., as well as a method for making such an orodispersible tablet.Type: GrantFiled: March 12, 2008Date of Patent: May 25, 2010Assignee: H. Lundbeck A/SInventors: Robert Dancer, Hans Petersen, Ole Nielsen, Michael Harold Rock, Helle Eliasen, Ken Liljegren
-
Patent number: 7560576Abstract: The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzo-furancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100° C., as well as a method for making such an orodispersible tablet.Type: GrantFiled: March 12, 2008Date of Patent: July 14, 2009Assignee: H. Lundbeck A/SInventors: Robert Dancer, Hans Petersen, Ole Nielsen, Michael Harold Rock, Helle Eliasen, Ken Liljegren
-
Publication number: 20080305164Abstract: Crystalline particles of escitalopram oxalate with a particle size of at least 40 ?m is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.Type: ApplicationFiled: August 22, 2008Publication date: December 11, 2008Applicant: H. LUNDBECK A/SInventors: Troels Volsgaard Christensen, Ken Liljegren, Michiel Onne Elema, Lene Andresen, Shashank Mahashabde, Sebastian P. Assenza
-
Patent number: 7420068Abstract: The present invention discloses crystalline particles of escitalopram oxalate which either have a broad particle size distribution or comprise at least 0.01% (w/w) of Z-4-(4-dimethylamino-1-(4-fluorophenyl)-but-1-enyl)-3-hydroxymethyl-benzonitrile, said particles being suitable for use in direct compression. Furthermore, the invention discloses a novel pharmaceutical unit dosage form containing such crystalline particles of escitalopram oxalate as well as methods for manufacture of such crystalline particles of escitalopram oxalate Finally, the invention provides a method for reduction of the amount of hydroxyl containing impurities in a solution of citalopram or escitalopram.Type: GrantFiled: September 23, 2004Date of Patent: September 2, 2008Assignee: H. Lundbeck A/SInventors: Kim Bojstrup Jensen, Rikke Eva Humble, Ken Liljegren, Troels Volsgaard Christensen
-
Patent number: 7420069Abstract: Crystalline particles of escitalopram oxalate with a particle size of at least 40 ?m is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.Type: GrantFiled: February 7, 2005Date of Patent: September 2, 2008Assignee: H. Lundbeck A/SInventors: Troels Volsgaard Christensen, Ken Liljegren, Michiel Onne Elema, Lene Andresen, Shashank Mahashabde, Sebastian P. Assenza
-
Publication number: 20080161388Abstract: The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzo-furancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100° C., as well as a method for making such an orodispersible tablet.Type: ApplicationFiled: March 12, 2008Publication date: July 3, 2008Applicant: H. LUNDBECK A/SInventors: Robert Dancer, Hans Petersen, Ole Nielsen, Michael Harold Rock, Helle Eliasen, Ken Liljegren
-
Publication number: 20080161584Abstract: The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzo-furancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100° C., as well as a method for making such an orodispersible tablet.Type: ApplicationFiled: March 12, 2008Publication date: July 3, 2008Applicant: H. LUNDBECK A/SInventors: Robert Dancer, Hans Petersen, Ole Nielsen, Michael Harold Rock, Helle Eliasen, Ken Liljegren
-
Publication number: 20070212412Abstract: The present invention relates to a pharmaceutical composition comprising sertindole and a protective agent absorbing radiation with a wavelenght below 400 nm. The present invention also relates to the use of sertindole for the preparation of a pharmaceutical composition comprising sertindole and a coating layer compsrising said protective agent, such as ironoxide, for the treatment of schizophrenia.Type: ApplicationFiled: September 8, 2006Publication date: September 13, 2007Applicant: H. Lundbeck A/SInventors: Flemming Olsen, Anne Christensen, Ken Liljegren
-
Publication number: 20070021499Abstract: The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100° C., as well as a method for making such an orodispersible tablet.Type: ApplicationFiled: June 21, 2006Publication date: January 25, 2007Applicant: H. Lundbeck A/SInventors: Robert Dancer, Hans Petersen, Ole Nielsen, Michael Rock, Helle Eliasen, Ken Liljegren
-
Publication number: 20050196453Abstract: The present invention discloses crystalline particles of escitalopram oxalate which either have a broad particle size distribution or comprise at least 0.01% (w/w) of Z-4-(4-dimethylamino-1-(4-fluorophenyl)-but-1-enyl)-3-hydroxymethyl-benzonitrile, said particles being suitable for use in direct compression. Furthermore, the invention discloses a novel pharmaceutical unit dosage form containing such crystalline particles of escitalopram oxalate as well as methods for manufacture of such crystalline particles of escitalopram oxalate Finally, the invention provides a method for reduction of the amount of hydroxyl containing impurities in a solution of citalopram or escitalopram.Type: ApplicationFiled: May 21, 2004Publication date: September 8, 2005Applicant: H. Lundbeck A/SInventors: Kim Jensen, Rikke Humble, Ken Liljegren, Troels Christensen
-
Publication number: 20050197388Abstract: The present invention discloses crystalline particles of escitalopram oxalate which either have a broad particle size distribution or comprise at least 0.01% (w/w) of Z-4-(4-dimethylamino-1-(4-fluorophenyl)-but-1-enyl)-3-hydroxymethyl-benzonitrile, said particles being suitable for use in direct compression. Furthermore, the invention discloses a novel pharmaceutical unit dosage form containing such crystalline particles of escitalopram oxalate as well as methods for manufacture of such crystalline particles of escitalopram oxalate Finally, the invention provides a method for reduction of the amount of hydroxyl containing impurities in a solution of citalopram or escitalopram.Type: ApplicationFiled: September 23, 2004Publication date: September 8, 2005Applicant: H. Lundbeck A/SInventors: Kim Jensen, Rikke Humble, Ken Liljegren, Troels Christensen
-
Patent number: 6916941Abstract: Crystalline particles of escitalopram oxalate with a particle size of at least 40 ?m is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.Type: GrantFiled: March 31, 2003Date of Patent: July 12, 2005Assignee: H. Lundbeck A/SInventors: Troels Volsgaard Christensen, Ken Liljegren, Michiel Onne Elema, Lene Andresen, Shashank Mahashabde, Sebastian P. Assenza
-
Publication number: 20050147674Abstract: Crystalline particles of escitalopram oxalate with a particle size of at least 40 ?m is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.Type: ApplicationFiled: February 7, 2005Publication date: July 7, 2005Inventors: Troels Christensen, Ken Liljegren, Michiel Elema, Lene Andresen, Shashank Mahashabde, Sebastian Assenza
-
Publication number: 20050053652Abstract: A solid unit dosage form comprising citalopram, which is prepared by direct compression of a mixture of citalopram base or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, or by filling of said mixture in a hard gelatine capsule. Large crystals of a pharmaceutical acceptable salt of citalopram and method for the manufacture of said large crystals.Type: ApplicationFiled: October 15, 2004Publication date: March 10, 2005Applicant: H. Lundbeck A/SInventors: Ken Liljegren, Per Holm, Ole Nielsen, Sven Wagner
-
Patent number: 6849659Abstract: A solid unit dosage form comprising citalopram, which is prepared by direct compression of a mixture of citalopram base or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, or by filling of said mixture in a hard gelatine capsule. Large crystals of a pharmaceutical acceptable salt of citalopram and method for the manufacture of said large crystals.Type: GrantFiled: December 5, 2000Date of Patent: February 1, 2005Assignee: H. Lundbeck A/SInventors: Ken Liljegren, Per Holm, Ole Nielsen, Sven Wagner
-
Publication number: 20040058989Abstract: A solid unit dosage form comprising citalopram which is prepared by a process comprising a step wherein citalopram base or a pharmaceutically acceptable salt thereof and optionally pharmaceutically acceptable excipients is roller compacted.Type: ApplicationFiled: July 1, 2003Publication date: March 25, 2004Applicant: H. Lundbeck A/SInventors: Ken Liljegren, Per Holm
-
Publication number: 20030232881Abstract: The invention is directed to methods of crystallizing pharmaceutically acceptable salts of citalopram, the resulting crystals, and pharmaceutical compositions comprising the crystals.Type: ApplicationFiled: December 5, 2002Publication date: December 18, 2003Applicant: H. LUNDBECK A/SInventors: Ken Liljegren, Per Holm, Ole Nielsen, Sven Wagner
-
Patent number: D842452Type: GrantFiled: July 22, 2017Date of Patent: March 5, 2019Assignee: H. Lundbeck A/SInventors: Cara Dignum, Ken Liljegren, Charlotte Miller